Lmcg Investments LLC Buys 9,484 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Lmcg Investments LLC lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 20.4% in the fourth quarter, Holdings Channel reports. The firm owned 55,949 shares of the medical equipment provider’s stock after buying an additional 9,484 shares during the period. Lmcg Investments LLC’s holdings in Zimmer Biomet were worth $5,910,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Equity Investment Corp purchased a new stake in Zimmer Biomet in the third quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its position in shares of Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock worth $189,161,000 after purchasing an additional 577,320 shares during the period. Magnetar Financial LLC increased its holdings in Zimmer Biomet by 58.7% during the second quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after buying an additional 484,816 shares during the period. Van ECK Associates Corp lifted its holdings in Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock worth $391,239,000 after buying an additional 411,163 shares during the period. Finally, Thompson Siegel & Walmsley LLC bought a new stake in Zimmer Biomet during the 3rd quarter valued at $41,588,000. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. BTIG Research lowered their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Wells Fargo & Company upped their target price on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Raymond James dropped their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. Royal Bank of Canada increased their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, November 4th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Stock Up 0.7 %

Shares of NYSE:ZBH opened at $109.65 on Tuesday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $100.67 and a fifty-two week high of $133.90. The firm’s 50 day moving average price is $107.84 and its 200 day moving average price is $108.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock has a market cap of $21.83 billion, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.65 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.